Form 4: SOPHiA GENETICS President Sells Shares for Tax Obligations
Insider Transaction Report
SOPHiA GENETICS President Ross Muken sold 1,183 ordinary shares on March 19, 2026, at a weighted average price of $4.7937 to cover tax obligations from RSU vesting.
Summary
- Ross Muken, President of SOPHiA GENETICS SA, reported a sale of ordinary shares.
- The transaction involved the disposition of 1,183 ordinary shares on March 19, 2026.
- The shares were sold at a weighted average price of $4.7937 per share, with prices ranging from $4.69 to $4.87.
- The sale was conducted to satisfy tax obligations associated with the vesting of restricted stock units (RSUs) on March 18, 2026.
- This transaction was executed pursuant to a pre-established Rule 10b5-1 trading plan and was not a discretionary trade.
- Following the reported transaction, Ross Muken beneficially owns 271,910 ordinary shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and for tax purposes, not indicative of a change in management's outlook on the company.
Industry Context
StockSavvy.ai notes that insider sales to cover tax obligations upon RSU vesting are a common and routine occurrence in the biotechnology and healthcare technology sectors, particularly for executives compensated with equity.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes and represents a small fraction of the insider's total holdings.
Key Dates
| Date | Description |
|---|---|
| 03/18/2026 | Restricted Stock Units (RSUs) vested. |
| 03/19/2026 | Transaction date for the sale of ordinary shares. |
| 03/20/2026 | Date the Form 4 was signed by the Attorney-in-fact for Ross Muken. |
Recommendation
holdThe transaction is a routine, non-discretionary sale by an insider to cover tax obligations from RSU vesting, executed under a Rule 10b5-1 plan. It does not reflect a change in the insider's confidence in the company or its future prospects, nor does it provide new operational or financial insights. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
SOPHiA GENETICS, SOPH, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Obligations, Rule 10b5-1 Plan, Ross Muken
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.